ROCHESTER, Minn., June 1, 2021 – Rion LLC, a clinical-stage biotech company focused on the development of highly effective and accessible regenerative medicines, announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, taking place virtually June 10-11 and 14-18. Rion is advancing in preclinical and clinical studies the company’s lead drug candidate, Purified Exosome Product (PEPTM), a room temperature stable regenerative medicine with the potential to drive tissue healing in conditions affecting millions of patients globally. PEP is an exosome therapeutic designed to activate the body’s innate ability to heal and is formulated to be easily administered and broadly accessible to patients.
Atta Behfar, M.D., Ph.D., cofounder of Rion, will present a company overview, which will be available on-demand to registered attendees starting at 9 am ET on June 10 until July 18. Attendees at BIO Digital will be able to view Rion’s company presentation before scheduled meetings in the BIO One-on-One PartneringTM system begin on June 14. To schedule a meeting with Rion at BIO Digital, please find registration information here.
BIO is the world’s largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Subscribe to Good Day BIO.
About PEPTM, an Exosome Therapeutic Platform
PEP (Purified Exosome ProductTM) is the world’s first clinical-grade room temperature stable, truly off-the-shelf regenerative medicine with the potential to drive tissue healing in conditions affecting millions of patients globally. The key to PEP’s efficacy and accessibility is Rion’s proprietary manufacturing process, which maintains exosome bioactivity and yields PEP as a powder that is pure, potent, and stable at room temperature for prolonged periods. This enables PEP to be administered in a wider range of clinical settings without the need for highly specialized equipment or infrastructure – a unique feature for regenerative medicine, typically requiring specialized tertiary care centers for storage and administration. Rion has established clinical-grade PEP CGMP manufacturing with customized formulations and routes of administration to target specific tissues and diseases.
Rion is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics that are clinically impactful and broadly accessible. Rion has developed Purified Exosome ProductTM (PEPTM), an innovative biologic platform that harnesses the therapeutic power of exosomes for regenerative medicine. Rion was established in 2017 through the Mayo Clinic Employee Entrepreneurial Program and is headquartered in Rochester, Minnesota.
Company Contact: Ryan Gordon, Sr. Vice President, Business Development email@example.comBack